VJHemOnc is committed to improving our service to you

iwCLL 2019 | The value of MRD assessment in CLL

VJHemOnc is committed to improving our service to you

Arnon Kater

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, explains the value of measurable residual disease (MRD) assessment for chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter